Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza, A; Cook, A; Pfisterer, J; Embleton, A; Ledermann, J; Pujade-Lauraine, E; Kristensen, G; Carey, M; Beale, P; Cervantes, A; Park-Simon, T; Rustin, G; Joly, F; Mirza, M; Plante, M; Quinn, M; Poveda, A; Jayson, Gordon C; Stark, D; Swart, A; Farrelly, L; Kaplan, R; Parmar, M; Perren, T

Affiliation

Princess Margaret Cancer Centre, Toronto, ON, Canada

Issue Date

2015-06-23

Metadata

Show full item record

Abstract

The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial.

Citation

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. 2015: Lancet Oncol

Journal

The Lancet. Oncology

URI

http://hdl.handle.net/10541/560789

DOI

10.1016/S1470-2045(15)00086-8

PubMed ID

26115797

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications